JPWO2023038088A1 - - Google Patents

Info

Publication number
JPWO2023038088A1
JPWO2023038088A1 JP2023546987A JP2023546987A JPWO2023038088A1 JP WO2023038088 A1 JPWO2023038088 A1 JP WO2023038088A1 JP 2023546987 A JP2023546987 A JP 2023546987A JP 2023546987 A JP2023546987 A JP 2023546987A JP WO2023038088 A1 JPWO2023038088 A1 JP WO2023038088A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023546987A
Other languages
Japanese (ja)
Other versions
JP7659282B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023038088A1 publication Critical patent/JPWO2023038088A1/ja
Application granted granted Critical
Publication of JP7659282B2 publication Critical patent/JP7659282B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • A61K38/063Glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D341/00Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023546987A 2021-09-09 2022-09-08 トリスルフィド化合物を用いる、肝細胞増殖因子中のチロシン残基のニトロ化を防止する方法 Active JP7659282B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021146753 2021-09-09
JP2021146753 2021-09-09
PCT/JP2022/033764 WO2023038088A1 (ja) 2021-09-09 2022-09-08 トリスルフィド化合物を用いる、肝細胞増殖因子中のチロシン残基のニトロ化を防止する方法

Publications (2)

Publication Number Publication Date
JPWO2023038088A1 true JPWO2023038088A1 (https=) 2023-03-16
JP7659282B2 JP7659282B2 (ja) 2025-04-09

Family

ID=85506410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546987A Active JP7659282B2 (ja) 2021-09-09 2022-09-08 トリスルフィド化合物を用いる、肝細胞増殖因子中のチロシン残基のニトロ化を防止する方法

Country Status (6)

Country Link
US (1) US20240374561A1 (https=)
EP (1) EP4400103A4 (https=)
JP (1) JP7659282B2 (https=)
CN (1) CN117915911A (https=)
TW (1) TW202321270A (https=)
WO (1) WO2023038088A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4647072A1 (en) * 2023-03-07 2025-11-12 Kyowa Hakko Bio Co., Ltd. Enhancer of physiological activity of hepatocyte growth factor
WO2025028521A1 (ja) 2023-08-01 2025-02-06 キリンホールディングス株式会社 肝機能障害の予防又は改善用組成物
CN118515869A (zh) * 2024-05-11 2024-08-20 四川大学 一种多硫化物聚合物、其制备方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087983A (ja) * 2000-09-14 2002-03-27 Toshiichi Nakamura 筋萎縮性側索硬化症治療剤
WO2018117186A1 (ja) * 2016-12-20 2018-06-28 協和発酵バイオ株式会社 グルタチオントリスルフィド・2水和物の結晶及びその製造方法
CN113354615A (zh) * 2020-03-02 2021-09-07 亚宝药业集团股份有限公司 一种α-硫辛酸杂质A的光化学制备方法
WO2021231476A1 (en) * 2020-05-12 2021-11-18 The General Hospital Corporation Glutathione trisulfide (gsssg) in neuroprotection
WO2022045212A1 (ja) * 2020-08-27 2022-03-03 協和ファーマケミカル株式会社 トリスルフィド化合物及びその包接体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018091689A1 (en) * 2016-11-17 2018-05-24 Cytoo Skeletal muscle hypertrophy inducers
JP2022074166A (ja) * 2019-01-30 2022-05-18 協和発酵バイオ株式会社 ポリスルフィド化合物を含有する組成物
EP4342464A4 (en) * 2021-07-08 2025-06-04 Kyowa Pharma Chemical Co., Ltd. PROPHYLACTIC OR THERAPEUTIC MEDICINE FOR PARKINSON'S DISEASE

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087983A (ja) * 2000-09-14 2002-03-27 Toshiichi Nakamura 筋萎縮性側索硬化症治療剤
WO2018117186A1 (ja) * 2016-12-20 2018-06-28 協和発酵バイオ株式会社 グルタチオントリスルフィド・2水和物の結晶及びその製造方法
CN113354615A (zh) * 2020-03-02 2021-09-07 亚宝药业集团股份有限公司 一种α-硫辛酸杂质A的光化学制备方法
WO2021231476A1 (en) * 2020-05-12 2021-11-18 The General Hospital Corporation Glutathione trisulfide (gsssg) in neuroprotection
WO2022045212A1 (ja) * 2020-08-27 2022-03-03 協和ファーマケミカル株式会社 トリスルフィド化合物及びその包接体

Also Published As

Publication number Publication date
CN117915911A (zh) 2024-04-19
WO2023038088A1 (ja) 2023-03-16
EP4400103A4 (en) 2025-08-20
JP7659282B2 (ja) 2025-04-09
US20240374561A1 (en) 2024-11-14
EP4400103A1 (en) 2024-07-17
TW202321270A (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
JPWO2023038088A1 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250319

R150 Certificate of patent or registration of utility model

Ref document number: 7659282

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150